V. Fikkert

发表

env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

E. De Clercq, C. Pannecouque, A. Vandamme, 2002, Antimicrobial Agents and Chemotherapy.

Antiviral resistance to diketo acids is associated with the mutations T66I, L74M and S230R in the HIV-1 integrase gene

C. Pannecouque, N. Neamati, T. Burke, 2002 .

The Budget Impact of Denosumab in the Treatment of Giant Cell Tumor of the Bone (Gctb) in Belgium.

Y. Qian, S. Vingerhoedt, V. Fikkert, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Mutations in Both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology

E. De Clercq, A. Vandamme, Z. Debyser, 2005, Antiviral chemistry & chemotherapy.

env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors

C. Pannecouque, A. Vandamme, K. Van Laethem, 2003, Antimicrobial Agents and Chemotherapy.

Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives

E. De Clercq, C. Pannecouque, N. Neamati, 2002, Antimicrobial Agents and Chemotherapy.

Identification of Authentic Inhibitors of HIV-1 Integration

J. Vercammen, Z. Debyser, Y. Engelborghs, 2005 .

Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.

E. De Clercq, C. Pannecouque, E. Clercq, 2000, Molecular pharmacology.

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360

E. De Clercq, C. Pannecouque, M. de Maeyer, 2004, AIDS.

Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations

E. De Clercq, C. Pannecouque, M. de Maeyer, 2003, Journal of Virology.

Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A

L. Stamatatos, E. De Clercq, C. Pannecouque, 2005, Journal of Virology.

Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.

Y. Pommier, E. De Clercq, C. Pannecouque, 2000, Molecular pharmacology.

Discovery of a small-molecule HIV-1 integrase inhibitor-binding site.

Myriam Witvrouw, Christoph H Borchers, Laith Q Al-Mawsawi, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Potent and Selective Inhibition of HIV and SIV by Prostratin Interacting with Viral Entry

E. De Clercq, C. Pannecouque, M. Witvrouw, 2003, Antiviral chemistry & chemotherapy.

Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A

L. Stamatatos, E. De Clercq, C. Pannecouque, 2005, Journal of Virology.